S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Pentagon debuts its new stealth bomber, the B-21 Raider
Prosecutor: Evidence shows Trump 'explicitly' OK'd tax fraud
Why Your IRA Could Crash on January 16th? (Ad)
Why CSL Ltd Stock Could Be Worth a Look
Group of Seven nations and Australia join EU in setting $60-per-barrel price cap on Russian oil
The Small Biotech Scaring Big Pharma (Ad)
Closing prices for crude oil, gold and other commodities
EXPLAINER: What's the effect of Russian oil price cap, ban?
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Pentagon debuts its new stealth bomber, the B-21 Raider
Prosecutor: Evidence shows Trump 'explicitly' OK'd tax fraud
Why Your IRA Could Crash on January 16th? (Ad)
Why CSL Ltd Stock Could Be Worth a Look
Group of Seven nations and Australia join EU in setting $60-per-barrel price cap on Russian oil
The Small Biotech Scaring Big Pharma (Ad)
Closing prices for crude oil, gold and other commodities
EXPLAINER: What's the effect of Russian oil price cap, ban?
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Pentagon debuts its new stealth bomber, the B-21 Raider
Prosecutor: Evidence shows Trump 'explicitly' OK'd tax fraud
Why Your IRA Could Crash on January 16th? (Ad)
Why CSL Ltd Stock Could Be Worth a Look
Group of Seven nations and Australia join EU in setting $60-per-barrel price cap on Russian oil
The Small Biotech Scaring Big Pharma (Ad)
Closing prices for crude oil, gold and other commodities
EXPLAINER: What's the effect of Russian oil price cap, ban?
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Pentagon debuts its new stealth bomber, the B-21 Raider
Prosecutor: Evidence shows Trump 'explicitly' OK'd tax fraud
Why Your IRA Could Crash on January 16th? (Ad)
Why CSL Ltd Stock Could Be Worth a Look
Group of Seven nations and Australia join EU in setting $60-per-barrel price cap on Russian oil
The Small Biotech Scaring Big Pharma (Ad)
Closing prices for crude oil, gold and other commodities
EXPLAINER: What's the effect of Russian oil price cap, ban?
NASDAQ:MBRX

Moleculin Biotech - MBRX Stock Forecast, Price & News

$1.35
-0.06 (-4.26%)
(As of 12/2/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.31
$1.43
50-Day Range
$0.87
$1.44
52-Week Range
$0.82
$2.33
Volume
54,206 shs
Average Volume
98,557 shs
Market Capitalization
$38.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.50

Moleculin Biotech MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
678.6% Upside
$10.50 Price Target
Short Interest
Healthy
0.24% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.20mentions of Moleculin Biotech in the last 14 days
Based on 4 Articles This Week
Insider Trading
Acquiring Shares
$166,132 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.06) to ($1.10) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.15 out of 5 stars

Medical Sector

497th out of 1,034 stocks

Pharmaceutical Preparations Industry

225th out of 502 stocks

MBRX stock logo

About Moleculin Biotech (NASDAQ:MBRX) Stock

Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company has partnership and collaboration agreements with MD Anderson; Animal Life Sciences, LLC; and WPD Pharmaceuticals Sp z.o.o. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.

Receive MBRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Moleculin Biotech and its competitors with MarketBeat's FREE daily newsletter.

MBRX Stock News Headlines

StockNews.com Initiates Coverage on Moleculin Biotech (NASDAQ:MBRX)
How to Invest in Biotechnology
Moleculin Biotech GAAP EPS of -$0.24
Moleculin Biotech Reports Q1 Result
See More Headlines
Receive MBRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Moleculin Biotech and its competitors with MarketBeat's FREE daily newsletter.

MBRX Company Calendar

Last Earnings
11/11/2021
Today
12/03/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/24/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MBRX
Fax
N/A
Employees
13
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.50
High Stock Price Forecast
$16.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+678.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-15,890,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.04 per share

Miscellaneous

Free Float
27,569,000
Market Cap
$38.61 million
Optionable
Not Optionable
Beta
1.90

Key Executives

  • Mr. Walter V. Klemp (Age 62)
    Founder, Chairman, Pres & CEO
    Comp: $891.66k
  • Mr. Jonathan P. Foster CPA (Age 58)
    Exec. VP & CFO
    Comp: $611.2k
  • Dr. Donald H. Picker Ph.D. (Age 76)
    Chief Scientific Officer
    Comp: $479.87k
  • Dr. Waldemar Priebe Ph.D.
    Co-Founder, Founding Scientist & Chairman of Scientific Advisory Board
  • Dr. Robert C. Shepard FACP (Age 70)
    M.D., F.A.C.P., Chief Medical Officer of Annamycin
  • Dr. John Paul Waymack M.D. (Age 70)
    Sc.D., Sr. Chief Medical Officer
  • Dr. Sandra L. Silberman M.D. (Age 67)
    Ph.D., Chief Medical Officer of New Products
  • Dr. Wolfram C. M. Dempke M.B.A.
    M.D., Ph.D., European Chief Medical Officer
  • Ms. Jacqueline Northcut (Age 60)
    Consultant
  • Mr. Louis Ploth Jr. (Age 68)
    Independent Advisor













MBRX Stock - Frequently Asked Questions

Should I buy or sell Moleculin Biotech stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Moleculin Biotech in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" MBRX shares.
View MBRX analyst ratings
or view top-rated stocks.

What is Moleculin Biotech's stock price forecast for 2023?

1 Wall Street research analysts have issued 1-year target prices for Moleculin Biotech's shares. Their MBRX share price forecasts range from $5.00 to $16.00. On average, they expect the company's stock price to reach $10.50 in the next twelve months. This suggests a possible upside of 678.6% from the stock's current price.
View analysts price targets for MBRX
or view top-rated stocks among Wall Street analysts.

How have MBRX shares performed in 2022?

Moleculin Biotech's stock was trading at $1.86 at the start of the year. Since then, MBRX stock has decreased by 27.5% and is now trading at $1.3486.
View the best growth stocks for 2022 here
.

Are investors shorting Moleculin Biotech?

Moleculin Biotech saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 68,000 shares, an increase of 32.0% from the October 31st total of 51,500 shares. Based on an average daily trading volume, of 114,200 shares, the days-to-cover ratio is presently 0.6 days. Currently, 0.2% of the company's shares are sold short.
View Moleculin Biotech's Short Interest
.

When is Moleculin Biotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 24th 2023.
View our MBRX earnings forecast
.

How were Moleculin Biotech's earnings last quarter?

Moleculin Biotech, Inc. (NASDAQ:MBRX) announced its quarterly earnings data on Thursday, November, 11th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.05.

When did Moleculin Biotech's stock split?

Moleculin Biotech shares reverse split on the morning of Monday, February 1st 2021. The 1-6 reverse split was announced on Friday, January 29th 2021. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 29th 2021. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

What other stocks do shareholders of Moleculin Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Moleculin Biotech investors own include Inovio Pharmaceuticals (INO), Rite Aid (RAD), VBI Vaccines (VBIV), Gilead Sciences (GILD), Novavax (NVAX), Co-Diagnostics (CODX), Dynavax Technologies (DVAX), OPKO Health (OPK), SCYNEXIS (SCYX) and Exelixis (EXEL).

What is Moleculin Biotech's stock symbol?

Moleculin Biotech trades on the NASDAQ under the ticker symbol "MBRX."

How do I buy shares of Moleculin Biotech?

Shares of MBRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Moleculin Biotech's stock price today?

One share of MBRX stock can currently be purchased for approximately $1.35.

How much money does Moleculin Biotech make?

Moleculin Biotech (NASDAQ:MBRX) has a market capitalization of $38.61 million. The company earns $-15,890,000.00 in net income (profit) each year or ($0.87) on an earnings per share basis.

How can I contact Moleculin Biotech?

Moleculin Biotech's mailing address is 5300 MEMORIAL DRIVE SUITE 950, HOUSTON TX, 77007. The official website for the company is www.moleculin.com. The company can be reached via phone at (713) 300-5160 or via email at jsalierno@theruthgroup.com.

This page (NASDAQ:MBRX) was last updated on 12/3/2022 by MarketBeat.com Staff